

CURRICULUM VITAE

Date : 20-FEB-2017

LASTNAME, Firstname CHIBAUDEL, Benoist
Address Franco-British Institute
Department of Medical Oncology - 4, rue Kléber
ZIP – City - Country 92300 - Levallois Perret - France
e-mail benoist.chibaudel@ihfb.org
Birthdate – City / Country November 4th, 1976–Poitiers / France
French Id RPPS / CNOM 10001639730 / 92-23781
Speciality Medical Oncology



Professional Activities

Department of Medical Oncology – Franco-British Institute, Levallois-Perret Since September 2014
Medical Oncologist
Assistant Head of Department of Medical Oncology (Pr Aimery de Gramont)

Department of Medical Oncology – Saint-Antoine Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France 2005-2014
Medical Oncologist

GERCOR, Groupe Coopérateur Multidisciplinaire en Oncologie, Paris 11 Since November 2006
Medical Director

AFR Oncology, Preclinical and Translational Research, Paris 10 Since October 2014

Licenses

Master's degree of Methodology and Biostatistics in Clinical Research – Paris 11 2013

Professional Qualification in Medical Oncology 2011

University Degree of Biostatistics (CESAM), Paris VI 2008

European Degree of pharmacovigilance, EudraVigilance Training Course, EMEA, London 2007

University Degree of Medical Oncology, Gustave Roussy Institute, Paris 11 2006

MedicalDegree 2005

Publications

1. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJ, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A; Analysis and Research in Cancers of the Digestive System (ARCAD) Group. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. *Lancet Oncol.* 2016 Dec;17(12):1709-1719.
2. Lapeyre-Prost A, Hug de Larauze M, Chibaudel B, Garcia ML, Guering-Meyer V, Bouché O, Boucher E, Ychou M, Dauba J, Obled S, Lièvre A, Malka D, Faroux R, Bonnet I, Taieb J, André T; Groupe Coopérateur Multidisciplinaire en Oncologie, the Fédération Francophone de la Cancérologie Digestive, and the UNICANCER Investigators of the PRODIGE Intergroup. Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal

3. Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem JL, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). *Br J Cancer*. 2016 Jul 26;115(3):281-9
4. Sebbagh S, Roux J, Dreyer C, Neuzillet C, de Gramont A, Orbegoso C, Hentic O, Hammel P, de Gramont A, Raymond E, André T, Chibaudel B, Faivre S. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. *ActaOncol*. 2016 Jun 22:1-7
5. HamidouZ, Chibaudel B, Hebbar M, Hug de Larauze M, André T, Louvet C, Brusquant D, Garcia-Larnicol ML, de Gramont A, Bonnetain F. Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial. *PLoS One*. 2016 Jun 16;11(6):e0157067
6. Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. *JAMA*. 2016 May 3;315(17):1844-53.
7. Lledo G, Huguet F, Chibaudel B, Di Fiore F, Mineur L, Galais MP, Artru P, Blondin V, Dupuis O, Abdiche MS, Jovenin N, Pozet A, Bonnetain F, Attia M, Dahan L, de Gramont A. Chemoradiotherapywith FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX. *Eur J Cancer*. 2016 Feb1;56:115-121
8. Chibaudel B, Maindrault-Göebel F, Bachet JB, Louvet C, Khalil A, Dupuis O, Hammel P, Garcia ML, Bennamoun M, Brusquant D, Tournigand C, André T, Arbaud C, Larsen AK, Wang YW, Yeh CG, Bonnetain F, de Gramont A. PEPOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. *Cancer Med*. 2016 Jan 24.
9. Lapeyre-Prost A, Hug de Larauze M, Chibaudel B, Garcia ML, Guering-Meyer V, Bouché O, Boucher E, Ychou M, Dauba J, Obled S, Lièvre A, Malka D, Faroux R, Bonnet I, Taieb J, André T; Groupe Coopérateur Multidisciplinaire en Oncologie, the Fédération Francophone de la Cancérologie Digestive, and the UNICANCER Investigators of the PRODIGE Intergroup. Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. *Clin Colorectal Cancer*. 2015 Dec 2.
10. Chibaudel B, Bonnetain F, Tournigand C, de Gramont A. Maintenance treatment in metastatic colorectal cancer. *Lancet Oncol*. 2015 Dec;16(16):e583-4.
11. Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. *TherAdv Med Oncol*. 2015 May;7(3):153-69.
12. André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scrivera A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. *J Clin Oncol*. 2015 Dec 10;33(35):4176-87.
13. Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. *J Clin Oncol*. 2016 Jan 10;34(2):144-50.
14. Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, deGramont A. Bevacizumab with or without erlotinib as maintenance therapy inpatients with metastatic colorectal cancer (GERCOR DREAM; OPTIMO3): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2015 Nov;16(15):1493-505.
15. Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V,

-
- Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). *Ann Oncol*. 2015 Dec;26(12):2505-6.
16. Bachet JB, Chibaudel B, Bonnetain F, Validire P, Hammel P, André T, Louvet C; GERCOR group. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. *BMC Cancer*. 2015 Oct 6;15:653.
 17. Chibaudel B, Bonnetain F, Tournigand C, de Larauze MH, de Gramont A, Laurent-Puig P, Paget J, Hadengue A, Notelet D, Benetkiewicz M, André T, de Gramont A. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. *BMC Cancer*. 2015 Jul 4;15:496.
 18. Cohen R, Cervera P, Svrcek M, Dumont C, Garcia ML, Chibaudel B, de Gramont A, Pocard M, Duval A, Fléjou JF, André T. [DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?]. *Bull Cancer*. 2015 Jun;102(6 Suppl 1):S72-81.
 19. Hebbbar M, Chibaudel B, André T, Mineur L, Smith D, Louvet C, Dutel JL, Ychou M, Legoux JL, Mabro M, Faroux R, Auby D, Brusquant D, Khalil A, Truant S, Hadengue A, Dalban C, Gayet B, Paye F, Pruvot FR, Bonnetain F, de Gramont A; Group Coopérateur Multidisciplinaire en Oncologie (GERCOR) Group. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial. *Ann Oncol*. 2015 May;26(5):1040.
 20. Soularue É, Cohen R, Tournigand C, Zaanen A, Louvet C, Bachet JB, Hentic O, Samalin E, Chibaudel B, de Gramont A, André T; for GERCOR. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. *Bull Cancer*. 2015 Apr;102(4):324-31.
 21. Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debléd M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault-Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. *Ann Oncol*. 2015 May;26(5):873-9.
 22. Chibaudel B, Lacave R, Lefevre M, Soussan P, Antoine M, Périé S, Belloc JB, Banal A, Albert S, Chabolle F, Céruse P, Baril P, Gatineau M, Housset M, Moukoko R, Benetkiewicz M, de Gramont A, Bonnetain F, Lacau St Guily J. Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study. *Cancer Med*. 2015 May;4(5):721-31.
 23. Hebbbar M, Chibaudel B, André T, Mineur L, Smith D, Louvet C, Dutel JL, Ychou M, Legoux JL, Mabro M, Faroux R, Auby D, Brusquant D, Khalil A, Truant S, Hadengue A, Dalban C, Gayet B, Paye F, Pruvot FR, Bonnetain F, Landi B, Flesch M, Carola E, Martin P, Vaillant E, de Gramont A; Group Coopérateur Multidisciplinaire en Oncologie (GERCOR) Group. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial. *Ann Oncol*. 2015 Feb;26(2):340-7.
 24. Shi Q, de Gramont A, Grothey A, Zalberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinnar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. *J Clin Oncol*. 2015 Jan 1;33(1):22-8.
 25. Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlitz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). *Eur J Cancer*. 2014 Nov;50(17):2983-93.
-

-
26. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C; Aide et Recherche en Cancérologie Digestive Foundation. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. *J Clin Oncol*. 2014 Sep 20;32(27):2975-84.
 27. Diouf M, Chibaudel B, Filleron T, Tournigand C, Hug de Larauze M, Garcia-Larnicol ML, Dumont S, Louvet C, Perez-Staub N, Hadengue A, de Gramont A, Bonnetain F. Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study. *Health Qual Life Outcomes*. 2014 May 13;12:69.
 28. Manceau G, Imbeaud S, Thiébaud R, Liébaert F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V, André T, Laurent-Puig P. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. *Clin Cancer Res*. 2014 Jun 15;20(12):3338-47.
 29. Vignot S, Thariat J; Étienne Bardet (GORTEC et coordinateur de l'intergroupe), Juliette Thariat (GORTEC), Dominique De Raucourt (GETTEC), Franck Jegoux (GETTEC), François Janot (GETTEC), Jean Lacau (GERCOR), Dominique Notelet (GERCOR), Benoist Chibaudel (GERCOR), Nadejda Vintonenko (manager Intergroupe), Jean Bourhis (GORTEC). [Otorhinolaryngology thematic issue. Presentation]. *Bull Cancer*. 2014 May;101(5):399.
 30. Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevis C, Auquier P, Westeel V, Fiteni F, Borg C, Bonnetain F. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? *Qual Life Res*. 2015 Jan;24(1):5-18.
 31. Thariat J, Jegoux F, Pointreau Y, Fayette J, Boisselier P, Blanchard P, Alfonsi M, Aupérin A, Bardet E, Bensadoun RJ, Garaud P, Geoffrois L, Graff P, Guigay J, Janot F, Lapeyre M, Lefebvre JL, Martin L, Racadot S, Rolland F, Sire C, Tao Y, Tuchais C, Chibaudel B, Girard-Calais MH, Cornely A, Vintonenko N, Calais G, De Raucourt D, Lacau Saint-Guilly J, Bourhis J. [Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]. *Bull Cancer*. 2013 Oct;100(10):983-97.
 32. André T, Chibaudel B. [Aflibercept (Zaltrap®) approved in metastatic colorectal cancer]. *Bull Cancer*. 2013 Oct;100(10):1023-5.
 33. Chibaudel B, Tournigand C, Bonnetain F, Maindrault-Goebel F, Lledo G, André T, Larsen AK, Bengrine-Lefevre L, Louvet C, de Gramont A. Platinum-sensitivity in metastatic colorectal cancer: towards a definition. *Eur J Cancer*. 2013 Dec;49(18):3813-20.
 34. Hebbbar M, Chibaudel B, André T, Louvet C, Smith D, Mineur L, Bennamoun M, Mabro M, Brusquant D, Bonnetain F, Pruvot FR, de Gramont A. Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study. *J Chemother*. 2013 Apr;25(2):104-11.
 35. Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C, Pierga JY, Hammel P. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. *Ann Oncol*. 2013 Aug;24(8):2057-61.
 36. André T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C, Bennamoun M, Artru P, Nguyen S, Ebenezer C, Aissat N, Cayre A, Penault-Llorca F, Laurent-Puig P, de Gramont A; GERCOR. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. *Ann Oncol*. 2013 Feb;24(2):412-9.
 37. Feb;24(2):412-9.
 38. Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, de Gramont A. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. *J Clin Oncol*. 2012 Sep 20;30(27):3353-60.
 39. Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. *Ther Adv Med Oncol*. 2012 Mar;4(2):75-89.
 40. de Gramont A, de Gramont A, Chibaudel B, Larsen AK, Tournigand C, André T; GERCOR French Oncology Research Group. The evolution of adjuvant therapy in the treatment of early-stage colon cancer. *Clin Colorectal Cancer*. 2011 Dec;10(4):218-26.
 41. Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, Allegra CJ, Goldberg RM, de
-

-
- Gramont A. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancérologie Digestive Group Study. *J Clin Oncol*. 2011 Nov 1;29(31):4199-204.
42. Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Mégaloophonos VF, Kamsu-Kom N, Petitprez A, Escargueil AE, Boudou P, Dumont S, Cervera P, Fléjou JF, André T, Tournigand C, Chibaudel B, de Gramont A, Larsen AK. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. *Clin Cancer Res*. 2011 Oct 15;17(20):6522-30.
 43. Chibaudel B, Bonnetain F, Tournigand C, Bengrine-Lefevre L, Teixeira L, Artru P, Desramé J, Larsen AK, André T, Louvet C, de Gramont A. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. *Oncologist*. 2011;16(9):1228-38.
 44. de Gramont A, de Gramont A, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, Louvet C, André T; GERCOR (French Oncology Research Group). From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. *Semin Oncol*. 2011 Aug;38(4):521-32.
 45. Bengrine-Lefevre L, Afchain P, Chibaudel B, Gervais H, Tournigand C, DeGramont A, Louvet C. [Nasal septum perforation and bevacizumab]. *Rev Med Interne*. 2011 Apr;32(4):e43-5.
 46. Chibaudel B, Tournigand C, André T, Larsen AK, de Gramont A. Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions. *Clin Colorectal Cancer*. 2010 Dec;9(5):269-73.
 47. Tournigand C, Bengrine-Lefevre L, Chibaudel B, de Gramont A. [Management of metastatic colorectal cancer]. *Rev Prat*. 2010 Oct 20;60(8):1103-7. French.
 48. Rousseau B, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, Louvet C, André T, de Gramont A; GERCOR (French Oncology Research Group). Stage II and stage III colon cancer: treatment advances and future directions. *Cancer J*. 2010 May-Jun;16(3):202-9.
 49. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. *Br J Clin Pharmacol*. 2010 Jan;69(1):58-66.
 50. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, de Gramont A. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. *J Clin Oncol*. 2009 Dec 1;27(34):5727-33.
 51. Chibaudel B, Tournigand C, Artru P, André T, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Rivera F, Perez-Staub N, Louvet C, de Gramont A. FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. *Ann Oncol*. 2009 Aug;20(8):1383-6.
 52. Afchain P, Chibaudel B, Lledo G, Selle F, Bengrine-Lefevre L, Nguyen S, Paitel JF, Mineur L, Artru P, André T, Louvet C. First-line simplified GEMOX(S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study. *Bull Cancer*. 2009 May;96(5):E18-22.

Clinical, Translational and Pre-clinical Research

Investigator Site Personnel ICH GCP Training Certificate (26-JUN-2015)

Coordinator / chairman of national & international prospective studies (phases I, II & III)

Principal Investigator (PI) of national and international studies (phase I, II & III)

Responsible of Pharmacovigilance Unit (GERCOR)

Member of INSERM U938, Hôpital Saint-Antoine, Paris 12, France

Member of AFR Oncology, Paris 10, France

Member of Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR), Paris, France

Member of ARCAD Group, Fondation d'Aide et Recherche en Cancérologie Digestive (A.R.CA.D)

Chibaudel ó 20-FEB-2017


Member European Society of Medical Oncology (ESMO)

Member of American Society of Clinical Oncology (ASCO)

Expert assessment for the French National Health Authority (Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), France)

February 20, 2017

Dr Benoist CHIBAUDEL

A handwritten signature in black ink, consisting of a long horizontal stroke that curves downwards and loops back to the right, ending in a vertical line.